Article

Evaluation of an AI-Based Digital Pathology Tool for Breast Cancer Recurrence Risk

2026-06-11

Abstract excerpt

<title>Abstract</title> <p>Purpose Hormone receptor-positive (HR+) breast cancer is the most common type among women in the United States. Multigene assays such as DX® (ODX) assess recurrence risk and chemotherapy benefit but are costly and time-consuming. This study evaluates the AI-powered PreciseBreast® (PDxBR) and compares its risk scoring with established tools. Methods This prospective pilot study was con...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 93f15be6-b257-5043-a469-fe79bd04536f
DOI: 10.21203/rs.3.rs-9829846/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Evaluation of an AI-Based Digital Pathology Tool for Breast Cancer Recurrence RiskDOI 10.21203/rs.3.rs-9829846/v1Read

PreciseBreast is prognostic for breast cancer recurrence in a 21-gene assay managed cohortSemantic proximity Read

Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer RecurrenceSemantic proximity Read

Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.Semantic proximity Read

Multimodal histopathologic models stratify hormone receptor-positive early breast cancerSemantic proximity Read

Multimodal Prediction of Breast Cancer Recurrence Assays and Risk of RecurrenceSemantic proximity Read

Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.Semantic proximity Read

High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancerSemantic proximity Read

Evaluation and comparison of different breast cancer prognosis scores based on gene expression dataSemantic proximity Read

Scoping Review: Emerging (Bio)markers for the Early Detection of Breast Cancer RecurrenceSemantic proximity Read

Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.Semantic proximity Read

Validation of the predictive ability for recurrence and the clinical utility of the 95-gene classifier (95GC) through an integrated analysis of five studies.Semantic proximity Read

Clinical Validation of RlapsRisk BC in an international multi-cohorts settingSemantic proximity Read